--- title: "U.S. stock market midday update: Instinct Bio down 35.40% on increased volume, no major negative news but unusual capital movement observed" type: "News" locale: "en" url: "https://longbridge.com/en/news/294078430.md" description: "Instinct Bio Technical fell 35.40%; Amgen rose 4.65%, with a transaction volume of USD 192 million; AbbVie rose 3.22%, with a transaction volume of USD 169 million; Gilead Sciences rose 2.97%, with a transaction volume of USD 139 million; Vertex Pharmaceuticals rose 1.14%, with a market value of USD 123 billion" datetime: "2026-07-28T13:58:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294078430.md) - [en](https://longbridge.com/en/news/294078430.md) - [zh-HK](https://longbridge.com/zh-HK/news/294078430.md) generator: "portal-rs" --- # U.S. stock market midday update: Instinct Bio down 35.40% on increased volume, no major negative news but unusual capital movement observed **U.S. Stock Market Midday Update** Instinct Bio Technical, down 35.40%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Amgen up 4.65%, with increased trading volume. Based on recent key news: 1. On July 25, the European Medicines Agency recommended the withdrawal of Tavneos' approval due to unreliable research data. Tavneos is used to treat severe ANCA-associated vasculitis, with an increase in cases involving severe liver damage, leading to market concerns about Amgen's drug safety and stock price volatility. 2. On July 28, analysts maintained a hold rating on Amgen, not included in the recommended buy list. Nevertheless, Amgen's stock price rose, possibly driven by market optimism about its future performance. 3. No other significant news recently. The pharmaceutical industry faces regulatory challenges, and market volatility has increased. AbbVie up 3.22%. Based on recent news: 1. On July 27, the U.S. stock market welcomed a busy week of earnings reports, with multiple companies, including AbbVie, set to announce results, along with the Federal Reserve's interest rate decisions, preliminary GDP estimates, June PCE data, and employment cost index. These policy signals, tech company performances, and inflation data may affect interest rate expectations and valuations, with capital possibly shifting towards large tech stocks, AI infrastructure, and interest rate-sensitive sectors, increasing volatility in the short term. 2. On July 25, AbbVie boasts an attractive 2.7% dividend yield, a robust pharmaceutical business, and a clear focus on dividend distribution, which enhances investor confidence. 3. On July 28, the recent market rebound may trigger "sell the news" volatility, but this should not deter long-term investors. Market capital flows towards large tech stocks and AI infrastructure. Gilead Sciences up 2.97%. Based on recent key news: 1. On July 23, RBC Capital analyst Brian Abrahams maintained a hold rating on Gilead Sciences, setting a target price of $120. Nevertheless, BMO Capital gave Gilead Sciences a buy rating on the same day, driving the stock price up. 2. On July 28, Gilead Sciences' HIV product sales are projected to reach $20.8 billion in 2025, a 6% year-over-year increase. This growth reflects the company's strong performance in the HIV treatment field, boosting market confidence. 3. On July 25, MarketBeat noted that Gilead Sciences was not included in the top analysts' recommended five stocks list; however, Gilead Sciences still received a moderate buy rating. The HIV treatment sector performs strongly, enhancing market confidence **Stocks Ranked Among the Top in Market Capitalization in the Industry** Futai Pharmaceutical rose by 1.14%. Based on recent key news: 1. On July 28, companies in the industry successfully executed diversification strategies, attracting capital inflows, while companies facing pipeline failures quickly adjusted their valuations. This market differentiation led to an increase in stock prices for companies like Futai Pharmaceutical, which excelled in diversification. 2. On July 25, analysts rated Futai Pharmaceutical as a moderate buy, but it was not included in the top recommended stocks list. This indicates a cautious market attitude towards its future performance; nevertheless, the stock price still saw an increase. The industry's diversification strategy attracted capital inflows ### Related Stocks - [BIOT.US](https://longbridge.com/en/quote/BIOT.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) ## Related News & Research - [Instinct Bio partners with Indonesia’s Parva Candela to expand cosmetics business](https://longbridge.com/en/news/295396196.md) - [Instinct Bio (Nasdaq: BIOT) Secures $150 Million Equity Funding to Advance Regenerative Medicine Platform and Strategic Growth | ACQC Stock News](https://longbridge.com/en/news/294079569.md) - [Instinct Bio Stock Slides After Hours: Here's What is Going on With BIOT](https://longbridge.com/en/news/294161543.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**